[1]杨开华,周乐源.非小细胞肺癌组织DCLK1 和Bmi-1 蛋白表达及其与三维适形放疗效果的相关性研究[J].现代检验医学杂志,2022,37(06):177-182+187.[doi:10.3969/j.issn.1671-7414.2022.06.034]
　YANG Kai-hua,ZHOU Le-yuan.Expressions of DCLK1 and Bmi-1 Proteins in Non-small Cell Lung Cancer Tissues and Their Relationship with the Effect of Three-dimensional Conformal Radiotherapy[J].Journal of Modern Laboratory Medicine,2022,37(06):177-182+187.[doi:10.3969/j.issn.1671-7414.2022.06.034]
点击复制

非小细胞肺癌组织DCLK1 和Bmi-1 蛋白表达及其与三维适形放疗效果的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年06期
页码:
177-182+187
栏目:
检验与临床
出版日期:
2022-11-15

文章信息/Info

Title:
Expressions of DCLK1 and Bmi-1 Proteins in Non-small Cell Lung Cancer Tissues and Their Relationship with the Effect of Three-dimensional Conformal Radiotherapy
文章编号:
1671-7414(2022)06-177-07
作者:
杨开华; 周乐源
(江南大学附属医院放疗科，江苏无锡 214000)
Author(s):
YANG Kai-hua; ZHOU Le-yuan
(Department of Radiotherapy, Affiliated Hospital of Jiangnan University, Jiangsu Wuxi 214000, China)
关键词:
非小细胞肺癌; 双肾上腺素样激酶1; B 细胞特异性莫洛氏鼠白血病病毒插入位点一; 三维适形放疗
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.06.034
文献标志码:
A
摘要:
目的 探讨非小细胞肺癌(non small cell lung cancer，NSCLC)组织双肾上腺素样激酶1(dou-blecortin-likekinase 1，DCLK1)、B 细胞特异性莫洛氏鼠白血病病毒插入位点一(B cell specific moloney leukemia virus insert site-1，Bmi-1)蛋白表达及其与三维适形放疗效果的关系。方法 选取2018 年6 月～ 2021 年1 月江南大学附属医院收治的102 例拟行三维适形放疗的NSCLC 患者和40 例肺错构瘤患者，分别记为恶性组和良性组。采用免疫组织化学法检测二组病灶组织DCLK1 和Bmi-1 蛋白表达，并对比两组病灶组织及恶性组中不同临床病理特征患者癌组织DCLK1和Bmi-1 蛋白阳性表达率。恶性组均予以三维适形放疗6 周，并评价其放疗效果。对比恶性组三维适形放疗无效与放疗有效患者癌组织DCLK1 和Bmi-1 蛋白阳性表达率，采用Logistic 多元回归分析探讨恶性组NSCLC 组织DCLK1 和Bmi-1 蛋白阳性表达与三维适形放疗效果的关系。结果 恶性组病灶组织DCLK1 阳性表达率(60.78% )和Bmi-1 蛋白阳性表达率(70.59%)均高于良性组(32.50%，35.00%)，差异具有统计学意义(χ2=9.224，15.241，均P ＜ 0.05)；临床Ⅲ～Ⅳ期、未/ 低分化、淋巴结转移患者的DCLK1 和Bmi-1 蛋白阳性表达率分别高于临床Ⅰ～Ⅱ期、高/ 中分化、无淋巴结转移患者，差异均有统计学意义(χ2=6.638，9.756，5.670；7.724，7.447，6.114，均P ＜ 0.05)；三维适形放疗有效率为67.65%，无效率为32.35%；临床分期Ⅲ～Ⅳ期(OR=5.414，95%CI=4.027~6.663)、未/ 低分化(OR=4.773，95%CI=3.156~5.974)、淋巴结转移(OR=5.307，95%CI=3.768~6.626)、癌组织DCLK1(OR=5.496，95%CI=3.967~6.882)和Bmi-1 蛋白(OR=5.624，95%CI=4.127~7.287)阳性表达均是恶性组三维适形放疗无效的危险因素(均P ＜ 0.05)。结论 NSCLC 组织DCLK1 和Bmi-1 蛋白阳性表达率高于肺良性肿瘤，且临床分期、分化程度、淋巴结转移、NSCLC 组织DCLK1 和Bmi-1 蛋白阳性表达均可影响NSCLC 患者三维适形放疗的效果。
Abstract:
Objective To investigate the expressions of dou-blecortin-like kinase 1 (DCLK1) and B cell specific moloney leukemia virus insert site-1 (Bmi-1) proteins in non small cell lung cancer (NSCLC) tissue and their relationship with the effect of three-dimensional conformal radiotherapy. Methods 102 NSCLC patients who were treated by three-dimensional conformal radiotherapy and 40 pulmonary hamartoma patients in Affiliated Hospital of Jiangnan University were selected from June 2018 to January 2021, and were recorded as malignant group and benign group respectively. Immunohistochemical method was used to detect the expressions of DCLK1 and Bmi-1 proteins in the two groups of lesion tissues, and the positive expression rates of DCLK1 and Bmi-1 proteins were compared between the two groups of lesion tissues and cancer tissues of patients with different clinicopathological features in malignant group. The malignant group was received three-dimensional conformal radiotherapy for 6 weeks, and the radiotherapy effect was evaluated. The positive expression rates of DCLK1 and Bmi-1 proteins in cancer tissues of patients with ineffective and effective three-dimensional conformal radiotherapy in malignant group were compared. Logistic multiple regression analysis was used to explore the relationship between the positive expressions of DCLK1 and Bmi-1 proteins in malignant group NSCLC tissue and the effect of three-dimensional conformal radiotherapy. Results The positive rates of DCLK1 (60.78%) and Bmi-1(70.59%) protein expressions in the lesions of the malignant group were higher than those in the benign group(32.50%，35.00%), the differences were statistically significant (χ2=9.224, 15.241，all P ＜ 0.05). The positive rates of DCLK1 and Bmi-1 protein expressions in patients with clinical stage III ～ IV, undifferentiated/poorly differentiated, and lymph node metastasis were respectively higher than clinical stage Ⅰ ～ Ⅱ , high/moderately differentiated patients without lymph node metastasis with statistically(χ2=6.638, 9.756, 5.670；7.724, 7.447, 6.114, all P ＜ 0.05). Three-dimensional conformal radiotherapy had an effective rate of 67.65% and an ineffective rate of 32.35%. Clinical stage Ⅲ～Ⅳ(OR=5.414, 95%CI=4.027~6.663), undifferentiated/poorly differentiated(OR=4.773, 95%CI=3.156~5.974), lymph node Metastasis (OR=5.307, 95%CI=3.768~6.626) and the positive expressions of DCLK1(OR=5.496, 95%CI=3.967~6.882)and Bmi-1 (OR=5.624, 95%CI=4.127~7.287)proteins in cancer tissues were risk factors for the ineffectiveness of three-dimensional conformal radiotherapy in the malignant group (all P ＜ 0.05). Conclusion The positive expression rates of DCLK1 and Bmi-1 proteins in NSCLC was higher than that in benign lung tumors. The clinical stage, degree of differentiation, lymph node metastasis and the positive expressions of DCLK1 and Bmi-1 proteins in NSCLC could affect the effect of three-dimensional conformal radiotherapy in NSCLC patients.

参考文献/References:

[1] 彭琦 , 程少鹏 , 陈辅萍．非小细胞肺癌组织中 NSE的基因表达及与患者临床特征的相关性研究 [J].现代检验医学杂志 , 2020, 35(3): 36-38. PENG Qi, CHENG Shaopeng, CHEN Fuping. Correlation between NSE gene expression and serum NSE level in tumor tissues and clinical characteristics of patients with non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2020,35(3):36-38.
[2] ZHANG Zhe, MAO Hongyan, WANG Xingwen, et al. Comparison of I125 seed brachytherapy (radioactive seed brachytherapy) joint three-dimensional conformal radiotherapy and stereotactic ablative radiotherapy on early nonsmall cell lung cancer[J]. Journal of Cancer Research and Therapeutics, 2020, 16(7): 1560-1568.
[3] 贾长河 , 谢毅 , 袁媛 , 等 .微管相关蛋白样激酶 1在胃癌组织中的表达及其临床意义 [J].安徽医药 , 2020, 24 (2): 271-275, 前插 2． JIA Changhe, XIE Yi, YUAN Yuan, et al. Expression and clinical pathological significance of doublecortin-like kinase 1 in gastric cancer tissue [J]. Anhui Medical and Pharmaceutical Journal, 2020, 24(2):271-275, front row 2.
[4] 成琼 , 郭艳萍 , 李真 , 等 .Bmi-1对肾癌细胞迁移侵袭能力的影响及机制 [J].中国药理学通报 , 2020, 36 (4): 514-519． CHENG Qiong, GUO Yanping, LI Zhen, et al. Effect of Bmi-1 on invasion and metastasis of renal cancer cells and its related mechanism [J]. Chinese Pharmacological Bulletin, 2020, 36(4):514-519.
[5] 陈贤真 , 乔建瓯．血清中 DCLK1在非小细胞肺癌中的表达及应用价值 [J].中国实验诊断学 , 2019, 23(11): 1924-1928. CHEN Xianzhen, QIAO Jianou. Expression of circulating DCLK1 level and clinical significance in non-small cell lung cancer [J]. Chinese Journal of Laboratory Diagnosis, 2019, 23(11):1924-1928.
[6] LIU Sida, YANG Yang, CHEN Lu, et al. MicroRNA-154 functions as a tumor suppressor in non-small cell lung cancer through directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1[J]. Oncology Letters, 2018, 15(6): 10098-10104.
[7] 石远凯 , 孙燕 . 临床肿瘤内科手册 [M]. 6版 .北京 :人民卫生出版社 , 2015:286. SHI Yuankai, SUN Yan. Handbook of Clinical Oncology [M]. 6th Ed. Beijing: People’s Health Publishing House, 2015:286.
[8] 中华人民共和国国家卫生健康委员会 .原发性肺癌诊疗规范 (2018年版 )[J].肿瘤综合治疗电子杂志 ,2019,5(3):100-120. National Health Commission of the People’s Republic of China .Primary lung cancer diagnosis and treatment specification(2018 edition)[J]. Journal of Multidisciplinary Cancer Management(Electronic Version), 2019,5(3):100-120.
[9] EISENHAUER E A, THERASSE P, BOGAERTS J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)][J]. Eur J Cancer, 2009, 45(2): 228-247.
[10] 郭燕 , 马骖 , 刘朝兴 , 等．养正消积胶囊辅助三维适形调强放疗治疗老年非小细胞肺癌患者疗效及对 T淋巴细胞亚群的影响 [J]．疑难病杂志 , 2019, 18(8)： 800-804． GUO Yan, MA Can, LIU Chaoxing, et al. Therapeutic effect of Yangzhengxiaoji capsule combined with three-dimensional conformal intensity modulated radio-therapy on elderly patients with non-small cell lung cancer and its effect on T lymphocyte subsets [J]. Chinese Journal of Difficult and Complicated Cases, 2019, 18(8):800-804.
[11] 方霖 .三维适形放射治疗Ⅲ期非小细胞肺癌的远期疗效 [J].实用癌症杂志 , 2019, 34(12): 1977-1979. FANG Lin. Long term efficacy of three dimensional conformal radiotherapy for stage Ⅲ non-small cell lung cancer [J]. The Practical Journal of Cancer , 2019, 34(12):1977-1979.
[12] 王峥 ,周琼芳 ,张红梅 ,等 . 三维适形放疗与调强放疗对晚期非小细胞肺癌患者血清肿瘤标志物及剂量学参数比较研究 [J]. 现代生物医学进展 ,2019,19(2):300-303,320. WANG Zheng, ZHOU Qiongfang, ZHANG Hongmei, et al. Comparison of serum tumor markers and dosimetric parameters between three dimensional-conformal radiotherapy and intensity modulated radiation therapy in patients with advanced non-small cell lung cancer [J]. Progress in Modern Biomedicine, 2019, 19(2): 300-303,320.
[13] 孙祝 ,雍翔 ,孙宇 ,等.调强放疗对比三维适形放疗治疗非小细胞肺癌的疗效及对血清 CEA, CYFRA21-1的影响 [J].实用癌症杂志 , 2020, 35(5): 774-777. SUN Zhu, YONG Xiang, SUN Yu, et al. Therapeutic effect of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for non-small cell lung cancer and its effect on serum CEA and CYFRA21-1 [J]. The Practical Journal of Cancer, 2020, 35(5):774-777.
[14] RAZI S, SADEGHI A, ASADI-LARI Z, et al. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner[J]. Clinical and Experimental Medicine, 2021, 21(1): 139-147.
[15] LI Jian, WANG Yunchao, GE Jiayun, et al. Doublecortin-like kinase 1 (DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) and is associated with metastasis and prognosis in pancreatic cancer[J]. Cellular Physiology and Biochemistry, 2018, 51(1): 262-277.
[16] PANNEERSELVAM J, MOHANDOSS P, PATEL R, et al. DCLK1 regulates tumor stemness and cisplatin resistance in non-small cell lung cancer via ABCD-Member-4[J]. Molecular Therapy Oncolytics, 2020, 18(18): 24-36.
[17] 陈明军 , 陈奇 , 周月鹏 .Bmi-1调控非小细胞肺癌细胞对顺铂的敏感性研究 [J].医学研究生学报 , 2019, 32(7): 710-714. CHEN Mingjun, CHEN Qi, ZHOU Yuepeng. Regulatory effects of Bmi-1 and MDR1 on the chemosensitivity of human non-small cell lung cancer cells to cisplatin [J]. Journal of Medical Postgraduates, 2019, 32(7):710-714.
[18] 孟存英 , 安太 , 史盛梅 , 等 .DCLK1,Bmi-1在结直肠癌中的表达及临床意义 [J].临床肿瘤学杂志 , 2018, 23(5): 419-423. MENG Cunying, AN Tai, SHI Shengmei, et al. Expression of DCLK1 and Bmi-1 in colorectal cancer and their clinical significance [J]. Chinese Clinical Oncology, 2018, 23(5):419-423.
[19] CAO Zhiyun, WEYGANT N, CHANDRAKESAN P, et al. Tuft and cancer stem cell marker DCLK1: A new target to enhance Anti-Tumor immunity in the tumor microenvironment[J]. Cancers, 2020, 12(12): 3801.
[20] YU Jing, CHEN Ling, BAO Zhenhua, et al. BMI-1 promotes invasion and metastasis in endometrial Adenocarcinoma and is a poor prognostic factor[J]. Oncology Reports, 2020, 43(5): 1630-1640.
[21] 李军华 , 贾向东 , 许天祥 , 等 .DCLK1对结直肠癌细胞化疗敏感性的影响及机制 [J].现代肿瘤医学 , 2019, 27(19): 3382-3386. LI Junhua, JIA Xiangdong, XU Tianxiang, et al. The effect and mechanism of DCLK1 on chemosensitivity of colorectal cancer cells [J]. Journal of Modern Oncology, 2019, 27(19):3382-3386.
[22] YOU Dong, WANG Dawei, LIU Peiji, et al. Micro RNA-498 inhibits the proliferation, migration and invasion of Gastric cancer through targeting BMI-1 and suppressing AKT pathway[J]. Human Cell, 2020, 33(2): 366-376.
[23] 李量 , 李小龙 , 王锋刚 , 等 .放疗对广泛期小细胞肺癌预后的影响及相关影响因素分析 [J].实用癌症杂志 , 2020, 35(5): 778-781.
LI Liang, LI Xiaolong, WANG Fenggang, et al. Effect of radiotherapy on prognosis of extensive small cell lung cancer and related influencing factors [J]. The Practical Journal of Cancer, 2020, 35(5):778-781.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(06):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(06):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(06):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目：无锡市首届“双百”中青年医疗卫生拔尖人才基金(BJ2020053)。
作者简介：杨开华(1979-)，男，硕士，副主任医师，研究方向：肺部肿瘤放射治疗，E-mail：ahh3785@aliyun.com。
通讯作者：周乐源(1978-)，男，硕士，主任医师，研究方向：肺部肿瘤放射治疗，E-mail：zhouleyuan99@126.com。
更新日期/Last Update: 2022-11-15